C. Herbert

发表

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib.

D. Schadendorf, P. Ascierto, M. Mandalà, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of glioblastoma multiforme with radiotherapy and concomitant and adjuvant temozolomide: translation of randomised controlled trial evidence into routine clinical practice.

M. Williams, K. Hopkins, M. Greenslade, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery.

J. Braybrooke, T. Robinson, L. Wade, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Sequential immunotherapy in melanoma: is it a realistic alternative to dual immunotherapy?

H. Winter, C. Herbert, Hannah Taylor, 2021, Melanoma research.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib.

D. Schadendorf, P. Ascierto, P. Rutkowski, 2019, European journal of cancer.

Treating brain metastases in melanoma: What is the optimal CNS-directed and systemic management?

H. Winter, C. Herbert, Hannah Taylor, 2021, Journal of radiosurgery and SBRT.

The unexpected burden of hypomagnesaemia in gynae-oncology chemotherapy clinics.

P. Cornes, C. Herbert, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

D. Schadendorf, P. Ascierto, M. Mandalà, 2018, The Lancet. Oncology.

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma

J. Panse, M. Sabel, R. Fietkau, 2021, British Journal of Cancer.

Thromboembolic events with cisplatin-based neoadjuvant chemotherapy for transitional cell carcinoma of urinary bladder.

D. Gillatt, E. Rowe, R. Persad, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Incidence of Node-Positive Non-small-Cell Lung Cancer Undergoing Sublobar Resection and the Role of Radiation in Its Management

J. Flickinger, T. Fitzgerald, W. Walsh, 2020, Frontiers in Oncology.

Dual Immunotherapy in a Patient with Rapidly Progressive Metastatic Melanoma Without Failure of Grafted Kidney

A. Gee, H. Winter, C. Herbert, 2022, EMJ Oncology.

Pre-diagnostic blood biomarkers for adult glioma

K. Kurian, L. J. Andrews, P. Davies, 2023, Frontiers in Oncology.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.

S. Halford, Juanita Lopez, S. Short, 2018 .

LBA7_PRBRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence

D. Schadendorf, P. Ascierto, M. Mandalà, 2017 .

ACTR-16. RESULTS OF THE OPARATIC TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS WITH RELAPSED GLIOBLASTOMA (GBM)

S. Halford, Juanita Lopez, S. Erridge, 2017 .